Literature DB >> 29847367

Epigenetics of pain mediators.

Daniel W Odell1.   

Abstract

PURPOSE OF REVIEW: The field of epigenetics continues its influential rise as a means to better understand an organism's unique developmental identity over a lifespan. Whereas a genome is constant and unchanging, an epigenome is dynamic and alterable. Epigenetic changes are in response to innumerable internal and external influences including environmental changes such as diet, exercise, disease, toxins, and stress. Epigenetics is of particular interest in the medical research community both for the potential to cause disease and as a target for therapeutic interventions. This article provides a succinct explanation of the potential for epigenetics to influence the understanding of pain as well as a review of relevant research on the topic. RECENT
FINDINGS: Studies on epigenetics and pain remain largely preclinical and investigate the theoretical ability of epigenetics to alter the nociceptive pathways both in the periphery and centrally. Significant evidence now exists for the ability of epigenetics to modify broadly categorized pain types, including inflammatory, neuropathic, visceral, and cancer related.
SUMMARY: Both patients and providers recognize that novel medications for the treatment of both acute and chronic pain conditions are sorely needed. The understanding of epigenetics and its influence on nociception remains in relative infancy but early evidence is strong for potential therapeutic benefits to treat these conditions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29847367     DOI: 10.1097/ACO.0000000000000613

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  6 in total

1.  Does epigenetic 'memory' of early-life stress predispose to chronic pain in later life? A potential role for the stress regulator FKBP5.

Authors:  S M Géranton
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-09-23       Impact factor: 6.237

2.  Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury.

Authors:  Vittoria Borgonetti; Elisabetta Meacci; Federica Pierucci; Maria Novella Romanelli; Nicoletta Galeotti
Journal:  Neurotherapeutics       Date:  2022-05-02       Impact factor: 6.088

Review 3.  Epigenetic modifications in neuropathic pain.

Authors:  Danzhi Luo; Xiaohong Li; Simin Tang; Fuhu Song; Wenjun Li; Guiling Xie; Jinshu Liang; Jun Zhou
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

4.  SIRT3-Mediated CypD-K166 Deacetylation Alleviates Neuropathic Pain by Improving Mitochondrial Dysfunction and Inhibiting Oxidative Stress.

Authors:  Binbin Yan; Qiang Liu; Xiaobao Ding; Yuwen Lin; Xiaowei Jiao; Yuqing Wu; Huihui Miao; Chenghua Zhou
Journal:  Oxid Med Cell Longev       Date:  2022-09-01       Impact factor: 7.310

Review 5.  Current Evidence on Potential Uses of MicroRNA Biomarkers for Migraine: From Diagnosis to Treatment.

Authors:  Parisa Gazerani
Journal:  Mol Diagn Ther       Date:  2019-12       Impact factor: 4.074

Review 6.  Adrenomedullin: an important participant in neurological diseases.

Authors:  Feng-Jiao Li; Si-Ru Zheng; Dong-Mei Wang
Journal:  Neural Regen Res       Date:  2020-07       Impact factor: 5.135

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.